"The US Food and Drug Administration (FDA) announced today that its review of two patients who died after receiving intramuscular injections of the schizophrenia drug olanzapine pamoate (Zyprexa Relprevv, Eli Lilly) is inconclusive, altho"...
DOSAGE AND ADMINISTRATION
Dosage must be individualized and adjusted according to the severity of the condition and the response obtained. As with all potent drugs, the best dose is the lowest dose that will produce the desired clinical effect. Since extrapyramidal symptoms increase in frequency and severity with increased dosage, it is important to employ the lowest effective dose. These symptoms have disappeared upon reduction of dosage, withdrawal of the drug, or administration of an antiparkinsonian agent.
Prolonged administration of doses exceeding 24 mg daily should be reserved for hospitalized patients or patients under continued observation for early detection and management of adverse reactions. An antiparkinsonian agent, such as trihexyphenidyl hydrochloride or benztropine mesylate, is valuable in controlling drug-induced extrapyramidal symptoms.
Suggested dosages for various conditions follow:
Moderately disturbed nonhospitalized patients with schizophrenia
4 to 8 mg t.i.d. initially; reduce as soon as possible to minimum effective dosage.
Hospitalized patients with schizophrenia
8 to 16 mg b.i.d. to q.i.d.; avoid dosages in excess of 64 mg daily.
Severe nausea and vomiting in adults
8 to 16 mg daily in divided doses; 24 mg occasionally may be necessary; early dosage reduction is desirable.
With increasing age, plasma concentrations of perphenazine (perphenazine) per daily ingested dose increase. Geriatric dosages of perphenazine (perphenazine) preparations have not been established, but initiation of lower dosages is recommended. Optimal clinical effect or benefit may require lower doses for a longer duration. Dosing of perphenazine (perphenazine) may occur before bedtime, if required.
Perphenazine (perphenazine) tablets, USP are round, unscored, film-coated white tablets available as:
2 mg: debossed GG 18 on one side and plain on the reverse side, supplied as:
NDC 0781-1046-01 bottles of 100 tablets
NDC 0781-1046-10 bottles of 1000 tablets
NDC 0781-1046-13 unit dose packages of 100 tablets
4 mg: debossed GG 107 on one side and plain on the reverse side, supplied as:
NDC 0781-1047-01 bottles of 100 tablets
NDC 0781-1047-05 bottles of 500 tablets
NDC 0781-1047-10 bottles of 1000 tablets
NDC 0781-1047-13 unit dose packages of 100 tablets
8 mg: debossed GG 108 on one side and plain on the reverse side, supplied as:
NDC 0781-1048-01 bottles of 100 tablets
NDC 0781-1048-05 bottles of 500 tablets
NDC 0781-1048-10 bottles of 1000 tablets
NDC 0781-1048-13 unit dose packages of 100 tablets
16 mg: debossed GG 109 on one side and plain on the reverse side, supplied as:
NDC 0781-1049-01 bottles of 100 tablets
NDC 0781-1049-10 bottles of 1000 tablets
NDC 0781-1049-13 unit dose packages of 100 tablets
Store at 20°-25°C (68°-77°F) (see USP Controlled Room Temperature). Dispense in a tight, light-resistant container.
Sandoz Inc. Princeton, NJ 08540. FDA Rev date: 10/22/2002This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 10/21/2008
Additional Perphenazine Tablets Information
Perphenazine Tablets - User Reviews
Perphenazine Tablets User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on therapy and treatment.